Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Hiroaki Nagano

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110385545. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
108
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper

Papers 12

  1. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  2. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  3. [A Case of Pancreatic Cancer with Concomitant Pancreatic Metastasis of Renal Cell Carcinoma]. Last author PMID 39948974↗
  4. The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers. Last author DOI 10.1080/14737159.2023.2281482↗
  5. [Treatment strategy for unresectable locally advanced pancreatic adenocarcinoma]. First author DOI 10.11405/nisshoshi.120.643↗
  6. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  7. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  8. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000511940↗
  9. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Mult… Co-author DOI 10.29337/ijsp.142↗
  10. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  11. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Last author DOI 10.1111/cas.13113↗
  12. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma. Co-author DOI 10.1177/0284185114549825↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Ioka · 3 shared papers, 2019–2024 · strength 0.65
  2. Yoshitaro Shindo · 3 shared papers, 2017–2024 · strength 0.48
  3. Kohei Nakata · 3 shared papers, 2023–2025 · strength 0.46
  4. Hiroshi Kurahara · 3 shared papers, 2023–2025 · strength 0.46
  5. Masao Nakajima · 2 shared papers, 2023–2024 · strength 0.43
  6. Yoshihiro Miyasaka · 3 shared papers, 2021–2025 · strength 0.43
  7. Hiroto Matsui · 3 shared papers, 2017–2024 · strength 0.35
  8. Makoto Ueno · 3 shared papers, 2019–2024 · strength 0.33
  9. Naoto Gotohda · 2 shared papers, 2024–2025 · strength 0.31
  10. Masafumi Nakamura · 2 shared papers, 2024–2025 · strength 0.31
  11. Naoki Ikenaga · 2 shared papers, 2023–2024 · strength 0.30
  12. Kazuyoshi Nishihara · 2 shared papers, 2021–2023 · strength 0.27
  13. Masafumi Nakamura · 2 shared papers, 2021–2023 · strength 0.27
  14. Susumu Eguchi · 2 shared papers, 2021–2023 · strength 0.27
  15. Masafumi Inomata · 2 shared papers, 2021–2023 · strength 0.27
  16. Hirokazu Noshirο · 2 shared papers, 2021–2023 · strength 0.27
  17. Takao Ohtsuka · 2 shared papers, 2021–2023 · strength 0.27
  18. Ryouichi Tsunedomi · 1 shared paper, 2023 · strength 0.24
  19. Kenichi Hakamada · 2 shared papers, 2019–2025 · strength 0.23
  20. Sohei Satoi · 2 shared papers, 2019–2025 · strength 0.23
  21. Itaru Endo · 2 shared papers, 2019–2025 · strength 0.23
  22. Yusaku Watanabe · 1 shared paper, 2024 · strength 0.20
  23. Hidenori Takahashi · 1 shared paper, 2024 · strength 0.20
  24. Akira Yakabe · 1 shared paper, 2024 · strength 0.20
  25. Takeshi Sudo · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.